Eden Research plc

February 16, 2011 02:00 ET

Debt conversion

                                                                                      16 February 2011
                                           EDEN RESEARCH PLC
                                         ("Eden" or "Company")

                                            Debt conversion

Eden  Research  plc, a leading UK agrochemical development company, is pleased to  announce  that  GBP
2,000,000  of  long term debt has been converted into 10,000,000 ordinary shares in the Company  at  a
price of 20p.

Following  this debt conversion, Eden has 82,986,200 ordinary shares in issue, of which the  Directors
are  interested in a total of 1,651,893 ordinary shares, representing 1.99 per cent of  the  Company's
enlarged issued share capital, as follows:

Director             No of shares held      % of enlarged share capital
A Abrey                        155,940                             0.19
K Brooks                       931,010                             1.12
B Gill                         385,848                             0.46
C Newitt                       179,095                             0.22

The Directors of Eden are responsible for the contents of this announcement.


Eden Research plc                                                        01993 862761
Clive Newitt, Managing Director

St Helens Capital Partners LLP                                           020 7368 6959
Mark Anwyl


Eden's strategy is focused on the development and commercialisation of its terpene-based encapsulation
technology  for  agricultural  and  non-agricultural  uses  through  appropriate  regional  or  global

Terpenes  are  natural  compounds which function as defence mechanisms in many plant  groups  and  are
released in response to infection, attack by pests, stress or mechanical injury. Terpenes are  already
widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically,  terpenes  have  had  limited commercial use in the agrochemical  sector  due  to  their
volatility,  phytotoxicity and poor solubility. Eden's platform encapsulation technology provides  the
unique,  natural  solution to these problems and enables terpenes to be used  as  effective,  low-risk

Contact Information

  • Eden Research plc